- Home
- BSET vs IKT Comparison
BSET vs IKT Comparison
Compare BSET & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSET
- IKT
- Stock Information
- Founded
- BSET 1902
- IKT 2008
- Country
- BSET United States
- IKT United States
- Employees
- BSET N/A
- IKT N/A
- Industry
- BSET Home Furnishings
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- BSET Consumer Discretionary
- IKT Health Care
- Exchange
- BSET Nasdaq
- IKT Nasdaq
- Market Cap
- BSET 134.7M
- IKT 159.2M
- IPO Year
- BSET 1987
- IKT 2020
- Fundamental
- Price
- BSET $14.38
- IKT $2.78
- Analyst Decision
- BSET
- IKT Strong Buy
- Analyst Count
- BSET 0
- IKT 2
- Target Price
- BSET N/A
- IKT $6.50
- AVG Volume (30 Days)
- BSET 10.6K
- IKT 288.1K
- Earning Date
- BSET 01-31-2025
- IKT 11-14-2024
- Dividend Yield
- BSET 5.69%
- IKT N/A
- EPS Growth
- BSET N/A
- IKT N/A
- EPS
- BSET N/A
- IKT N/A
- Revenue
- BSET $340,285,000.00
- IKT $1.00
- Revenue This Year
- BSET N/A
- IKT N/A
- Revenue Next Year
- BSET $1.77
- IKT N/A
- P/E Ratio
- BSET N/A
- IKT N/A
- Revenue Growth
- BSET N/A
- IKT N/A
- 52 Week Low
- BSET $12.11
- IKT $1.12
- 52 Week High
- BSET $16.50
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- BSET 56.27
- IKT 44.07
- Support Level
- BSET $13.66
- IKT $2.62
- Resistance Level
- BSET $14.47
- IKT $2.89
- Average True Range (ATR)
- BSET 0.30
- IKT 0.28
- MACD
- BSET 0.06
- IKT -0.06
- Stochastic Oscillator
- BSET 89.27
- IKT 23.94
About BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.